Table 3 Certainty of evidence for the association between metabolic obesity phenotypes and overall and specific cancer risk.
Certainty assessment | Relative risk (95% CI) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Outcome | No of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision (ratio of the upper to lower 95%CI) | Publication bias | Large magnitude of association | Other considerations | Certainty | |
MUNW vs. MHNW | |||||||||||
Overall | 3 | Cohort study | Not likely | Not likely | Not likely | Serious | Not likely | No upgrade | None | 1.09 (0.90–1.33) | Moderate |
Postmenopausal BC | 8 | Cohort study | Not likely | Not likely | Not likely | Not likely | Not likely | No upgrade | None | 1.08 (1.03–1.14) | High |
Endometrial | 4 | Cohort study | Not likely | Not likely | Not likely | Not likely | Not likely | No upgrade | None | 1.12 (1.02–1.24) | High |
Colorectal | 6 | Cohort study | Not likely | Not likely | Not likely | Not likely | Not likely | No upgrade | None | 1.14 (1.06–1.23) | High |
Colon | 5 | Cohort study | Not likely | Not likely | Not likely | Not likely | Not likely | No upgrade | None | 1.12 (1.06–1.17) | High |
Rectum | 3 | Cohort study | Not likely | Serious | Not likely | Not likely | Not likely | No upgrade | None | 1.13 (1.00–1.29) | Moderate |
Thyroid | 4 | Cohort study | Not likely | Not likely | Not likely | Not likely | Not likely | No upgrade | None | 1.06 (1.03–1.10) | High |
Pancreatic | 3 | Cohort study | Not likely | Not likely | Not likely | Not likely | Not likely | No upgrade | None | 1.35 (1.17–1.56) | High |
Kidney | 3 | Cohort study | Not likely | Not likely | Not likely | Not likely | Not likely | No upgrade | None | 1.29 (1.13–1.47) | High |
Gastric | 2 | Cohort study | Not likely | Not likely | Not likely | Serious | Not likely | No upgrade | None | 1.11 (0.75–1.62) | Moderate |
Bladder | 2 | Cohort study | Not likely | Not likely | Not likely | Not likely | Not likely | No upgrade | None | 1.18 (1.14–1.23) | High |
Prostate | 2 | Cohort study | Not likely | Very serious | Not likely | Serious | Not likely | No upgrade | None | 1.04 (0.85–1.27) | Very low |
Ovarian | 2 | Cohort study | Not likely | Not likely | Not likely | Serious | Not likely | No upgrade | None | 1.05 (0.91–1.21) | Moderate |
Myeloma | 2 | Cohort study | Not likely | Very serious | Not likely | Serious | Downgrade | No upgrade | None | 0.79 (0.45–1.41) | Very low |
Liver | 2 | Cohort study | Not likely | Not likely | Not likely | Not likely | Not likely | No upgrade | None | 1.33 (1.05–1.69) | High |
Gallbladder | 2 | Cohort study | Not likely | Not likely | Not likely | Serious | Not likely | No upgrade | None | 1.23 (0.92–1.64) | Moderate |
Obesity-related cancer | 3 | Cohort study | Not likely | Serious | Not likely | Serious | Not likely | No upgrade | None | 1.11 (1.00–1.24) | Moderate |
Premenopausal BC | 1 | Cohort study | Not likely | Not likely | Not likely | Serious | Not likely | No upgrade | None | 0.89 (0.48–1.65) | |
MHOW/OB vs. MHNW | |||||||||||
Overall | 3 | Cohort study | Not likely | Not likely | Not likely | Serious | Not likely | No upgrade | None | 1.10 (0.90–1.34) | Moderate |
Postmenopausal BC | 7 | Cohort study | Not likely | Serious | Not likely | Not likely | Not likely | No upgrade | None | 1.19 (1.12–1.26) | Moderate |
Endometrial | 4 | Cohort study | Not likely | Not likely | Not likely | Not likely | Not likely | No upgrade | None | 1.71 (1.58–1.85) | High |
Colorectal | 6 | Cohort study | Not likely | Serious | Not likely | Not likely | Not likely | No upgrade | None | 1.08 (1.00–1.17) | Moderate |
Colon | 3 | Cohort study | Not likely | Not likely | Not likely | Serious | Not likely | No upgrade | None | 1.16 (0.93–1.46) | Moderate |
Rectum | 2 | Cohort study | Not likely | Not likely | Not likely | Serious | Not likely | No upgrade | None | 1.02 (0.93–1.11) | Moderate |
Thyroid | 4 | Cohort study | Not likely | Not likely | Not likely | Not likely | Not likely | No upgrade | None | 1.27 (1.18–1.37) | High |
Pancreatic | 3 | Cohort study | Not likely | Serious | Not likely | Not likely | Not likely | No upgrade | None | 1.17 (1.10–1.37) | Moderate |
Kidney | 3 | Cohort study | Not likely | Not likely | Not likely | Not likely | Not likely | No upgrade | None | 1.35 (1.23–1.49) | High |
Gastric | 2 | Cohort study | Not likely | Not likely | Not likely | Serious | Not likely | No upgrade | None | 1.14 (0.80–1.61) | Moderate |
Bladder | 2 | Cohort study | Not likely | Not likely | Not likely | Not likely | Not likely | No upgrade | None | 1.07 (1.02–1.12) | High |
Prostate | 2 | Cohort study | Not likely | Very serious | Not likely | Serious | Not likely | No upgrade | None | 1.02 (0.88–1.19) | Very low |
Ovarian | 2 | Cohort study | Not likely | Not likely | Not likely | Serious | Not likely | No upgrade | None | 1.12 (0.99–1.25) | Moderate |
Myeloma | 2 | Cohort study | Not likely | Serious | Not likely | Serious | Not likely | No upgrade | None | 1.15 (0.90–1.48) | Low |
Liver | 2 | Cohort study | Not likely | Not likely | Not likely | Not likely | Not likely | No upgrade | None | 1.25 (1.04–1.51) | High |
Gallbladder | 2 | Cohort study | Not likely | Not likely | Not likely | Not likely | Not likely | No upgrade | None | 1.48 (1.19–1.85) | High |
Obesity-related cancer | 3 | Cohort study | Not likely | Serious | Not likely | Not likely | Downgrade | No upgrade | None | 1.17 (1.09–1.26) | Low |
Premenopausal BC | 1 | Cohort study | Not likely | Not likely | Not likely | Serious | Not likely | No upgrade | None | 0.94 (0.67–1.32) | |
MUOW/OB vs. MHNW | |||||||||||
Overall | 3 | Cohort study | Not likely | Not likely | Not likely | Not likely | Not likely | No upgrade | None | 1.21 (1.02–1.44) | High |
Postmenopausal BC | 7 | Cohort study | Not likely | Very serious | Not likely | Not likely | Not likely | No upgrade | None | 1.32 (1.17–1.48) | Low |
Endometrial | 4 | Cohort study | Not likely | Serious | Not likely | Not likely | Not likely | Upgrade (strong association) | None | 2.31 (2.08–2.57) | High |
Colorectal | 6 | Cohort study | Not likely | Serious | Not likely | Not likely | Not likely | No upgrade | None | 1.24 (1.16–1.31) | Moderate |
Colon | 3 | Cohort study | Not likely | Not likely | Not likely | Not likely | Not likely | No upgrade | None | 1.35 (1.27–1.43) | High |
Rectum | 2 | Cohort study | Not likely | Not likely | Not likely | Not likely | Not likely | No upgrade | None | 1.18 (1.10–1.27) | High |
Thyroid | 4 | Cohort study | Not likely | Not likely | Not likely | Not likely | Downgrade | No upgrade | None | 1.42 (1.29–1.57) | Moderate |
Pancreatic | 3 | Cohort study | Not likely | Not likely | Not likely | Not likely | Not likely | No upgrade | None | 1.35 (1.24–1.47) | High |
Kidney | 3 | Cohort study | Not likely | Very serious | Not likely | Not likely | Not likely | No upgrade | None | 1.71 (1.40–2.1) | Low |
Gastric | 2 | Cohort study | Not likely | Not likely | Not likely | Not likely | Not likely | No upgrade | None | 1.50 (1.12–2.01) | High |
Bladder | 2 | Cohort study | Not likely | Not likely | Not likely | Not likely | Not likely | No upgrade | None | 1.36 (1.19–1.56) | High |
Prostate | 2 | Cohort study | Not likely | Very serious | Not likely | Serious | Not likely | No upgrade | None | 1.05 (0.74–1.48) | Very low |
Ovarian | 2 | Cohort study | Not likely | Not likely | Not likely | Serious | Not likely | No upgrade | None | 1.08 (0.97–1.20) | Moderate |
Myeloma | 2 | Cohort study | Not likely | Serious | Not likely | Serious | Not likely | No upgrade | None | 1.06 (0.85–1.31) | Low |
Liver | 2 | Cohort study | Not likely | Serious | Not likely | Not likely | Not likely | No upgrade | None | 1.81 (1.36–2.42) | Moderate |
Gallbladder | 2 | Cohort study | Not likely | Not likely | Not likely | Not likely | Not likely | No upgrade | None | 1.42 (1.17–1.73) | High |
Obesity-related cancer | 3 | Cohort study | Not likely | Very serious | Not likely | Not likely | Downgrade | No upgrade | None | 1.42 (1.15–1.74) | Very low |
Premenopausal BC | 1 | Cohort study | Not likely | Not likely | Not likely | Serious | Not likely | No upgrade | None | 0.71 (0.52–0.97) | |
